Literature DB >> 7918477

Marked interspecies variations concerning the interactions of camptothecin with serum albumins: a frequency-domain fluorescence spectroscopic study.

Z Mi1, T G Burke.   

Abstract

Camptothecin, an anticancer agent reknown for its novel mechanism of action and outstanding murine in vivo activity, has to date displayed only modest therapeutic utility against human cancers. The drug contains an delta-lactone ring moiety which, at pH7.4, hydrolyzes to yield a biologically inactive carboxylate form. Comparison of drug stability in both plasma and purified serum albumin samples revealed that ring opening occurred to a much greater extent in human samples versus those of other species. Multifrequency phase-modulation spectroscopic analyses of the intrinsic fluorescence emissions of the two drug forms revealed a physical explanation for the extensive ring opening observed in the presence of human serum albumin (HSA): the protein exhibited a marked 200-fold binding preference for the carboxylate (K = 1.2 x 10(6) M-1) relative to the lactone (K approximately 5.5 x 10(3) M-1). Serum albumins from other species were found to bind camptothecin carboxylate not nearly as tightly as HSA. Due to the unique capacity of human albumin to bind camptothecin carboxylate, resulting in extensive conversion of the drug to its biologically inactive form, it appears that the success of the agent in eradicating cancer in animal models may be inherently more difficult to duplicate in man.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7918477     DOI: 10.1021/bi00208a002

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  16 in total

1.  In vitro binding and partitioning of irinotecan (CPT-11) and its metabolite, SN-38, in human blood.

Authors:  O Combes; J Barré; J C Duché; L Vernillet; Y Archimbaud; M P Marietta; J P Tillement; S Urien
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

2.  Anticancer Camptothecin-N-Poly(lactic acid) Nanoconjugates with Facile Hydrolysable Linker.

Authors:  Qian Yin; Rong Tong; Lichen Yin; Timothy M Fan; Jianjun Cheng
Journal:  Polym Chem       Date:  2014       Impact factor: 5.582

3.  High-Capacity Drug Carriers from Common Polymer Amphiphiles.

Authors:  Zhun Zhou; Oliver Munyaradzi; Xin Xia; Da'Sean Green; Dennis Bong
Journal:  Biomacromolecules       Date:  2016-08-23       Impact factor: 6.988

4.  Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies.

Authors:  Eric X Chen; Gerald Batist; Lillian L Siu; Naeema Bangash; Martha Maclean; Lynn McIntosh; Wilson H Miller; Amit M Oza; Chetan Lathia; Oana Petrenciuc; Lesley Seymour
Journal:  Invest New Drugs       Date:  2005-10       Impact factor: 3.850

5.  Topoisomerase I-mediated DNA cleavage induced by the minor groove-directed binding of bibenzimidazoles to a distal site.

Authors:  Qasim A Khan; Daniel S Pilch
Journal:  J Mol Biol       Date:  2006-10-13       Impact factor: 5.469

6.  Controlled synthesis of camptothecin-polylactide conjugates and nanoconjugates.

Authors:  Rong Tong; Jianjun Cheng
Journal:  Bioconjug Chem       Date:  2010-01       Impact factor: 4.774

7.  Liquid proliposomes of nimodipine drug delivery system: preparation, characterization, and pharmacokinetics.

Authors:  Chuandi Sun; Ji Wang; Jianping Liu; Lu Qiu; Wenli Zhang; Lei Zhang
Journal:  AAPS PharmSciTech       Date:  2013-01-15       Impact factor: 3.246

8.  Single-antibody, targeted nanoparticle delivery of camptothecin.

Authors:  Han Han; Mark E Davis
Journal:  Mol Pharm       Date:  2013-05-29       Impact factor: 4.939

9.  Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle.

Authors:  Scott Eliasof; Douglas Lazarus; Christian G Peters; Roy I Case; Roderic O Cole; Jungyeon Hwang; Thomas Schluep; Joseph Chao; James Lin; Yun Yen; Han Han; Devin T Wiley; Jonathan E Zuckerman; Mark E Davis
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-26       Impact factor: 11.205

10.  Plasma and tissue disposition of non-liposomal DB-67 and liposomal DB-67 in C.B-17 SCID mice.

Authors:  William C Zamboni; Laura L Jung; Sandra Strychor; Erin Joseph; Beth A Zamboni; Sarah A Fetterman; Brian J Sidone; Thomas G Burke; Dennis P Curran; Julie L Eiseman
Journal:  Invest New Drugs       Date:  2008-02-02       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.